Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;97(6):695-702.
doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

Neha Bhagwat  1 , Ross L Levine, Priya Koppikar
Affiliations
Review

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

Neha Bhagwat et al. Int J Hematol. 2013 Jun.

Abstract

The discovery of activating mutations in JAK2 and MPL in a majority of patients with myeloproliferative neoplasms (MPN) has led to the rapid clinical development of several JAK kinase inhibitors. Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF). JAK inhibitors have effectively reduced splenomegaly and high cytokine levels in patients leading to improvements in quality of life. However, they have not been successful in eliminating the mutant clone in a majority of patients. In vitro studies using saturation mutagenesis screens have revealed several mutations in JAK2 that confer resistance to JAK inhibitors. Nevertheless, these mutations have not been identified so far in JAK inhibitor-treated patients. A recent study from our laboratory demonstrated that chronic JAK kinase inhibition leads to JAK inhibitor persistence via transphosphorylation of JAK2 through other JAK kinase family members. This phenomenon is seen in cell lines, mouse models and patient samples. The JAK inhibitor persistent cells, however, still remain JAK2 dependent and therefore combination therapies that target JAK2 and other components of the JAK-STAT pathway along with JAK inhibitors may provide additional benefits and improve clinical outcomes in these patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Rev Cancer. 2012 Sep;12(9):599-612 - PubMed
    1. Nature. 2009 Oct 8;461(7265):819-22 - PubMed
    1. J Clin Oncol. 2013 Apr 1;31(10):1285-92 - PubMed
    1. Nat Struct Mol Biol. 2011 Aug 14;18(9):971-6 - PubMed
    1. Mol Cancer Ther. 2013 May;12(5):577-88 - PubMed

MeSH terms

LinkOut - more resources